Investment Firm Accelerator Launches miRNA Drug Developer, Licenses Nanogen MGB Tech

The company, called Mirina, will develop microRNA antagonists that have been modified with minor groove binders, which are expected to boost the oligos’ target selectivity and potency. The agreement with Nanogen marks the first time the company has licensed its MGB assets for therapeutic applications.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.